Great Point Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Great Point Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.3M	Hold	1,750,000	–	–	5.59%	4
2025 Q4	$21.1M	Buy	1,750,000 +50,000	+3%	+$679K	6.85%	2
2025 Q3	$23.1M	Sell	1,700,000 -300,000	-15%	-$2.82M	9.53%	1
2025 Q2	$12.8M	Buy	2,000,000 +188,004	+10%	+$914K	8.34%	3
2025 Q1	$6.41M	Buy	+1,811,996	New	+$6.45M	3.4%	12
2023 Q3	–	Sell	-968,795	Closed	-$20.9M	–	44
2023 Q2	$20.9M	Buy	968,795 +185,000	+24%	+$5M	4.09%	8
2023 Q1	$23M	Buy	783,795 +593,795	+313%	+$20.6M	4.52%	8
2022 Q4	$7.02M	Buy	+190,000	New	+$6.74M	1.38%	26

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Great Point Partners's AMLX Position: Q1 2026 in Review

Great Point Partners held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 1,750,000 shares worth $24.3M. The position accounts for 5.59% of the portfolio, ranked #4.

Great Point Partners first reported a position in AMLX in Q4 2022 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Great Point Partners held 1,750,000 shares of Amylyx Pharmaceuticals worth $24.3M as of Q1 2026.
Great Point Partners left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
Amylyx Pharmaceuticals made up 5.59% of Great Point Partners's portfolio in Q1 2026, its #4 holding.
Great Point Partners first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.